Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
MLNT

Melinta Therapeutics

$1.08

-0.08 (-6.90%)

09:25
12/20/18
12/20
09:25
12/20/18
09:25
Conference/Events
Melinta Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

MLNT

Melinta Therapeutics

$1.08

-0.08 (-6.90%)

09:13
12/20/18
12/20
09:13
12/20/18
09:13
Downgrade
Melinta Therapeutics rating change at Gabelli »

Melinta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

MLNT

Melinta Therapeutics

$1.08

-0.08 (-6.90%)

04:55
12/20/18
12/20
04:55
12/20/18
04:55
Conference/Events
Melinta Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

MLNT

Melinta Therapeutics

$1.16

-0.06 (-4.92%)

08:33
12/19/18
12/19
08:33
12/19/18
08:33
Hot Stocks
Melinta Therapeutics announces John Johnson as permanent CEO »

Melinta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

MLNT

Melinta Therapeutics

$1.19

-0.1 (-7.75%)

16:02
12/16/18
12/16
16:02
12/16/18
16:02
Conference/Events
Melinta Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNT

Melinta Therapeutics

$2.48

-0.11 (-4.25%)

08:08
11/27/18
11/27
08:08
11/27/18
08:08
Hot Stocks
Melinta Therapeutics granted EU marketing authorization for Vabomere »

Melinta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

MLNT

Melinta Therapeutics

$2.67

-0.125 (-4.47%)

07:09
11/07/18
11/07
07:09
11/07/18
07:09
Earnings
Melinta Therapeutics reports Q3 EPS (50c), consensus (94c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 27

    Nov

MLNT

Melinta Therapeutics

$2.90

0.02 (0.69%)

17:16
11/02/18
11/02
17:16
11/02/18
17:16
Hot Stocks
Breaking Hot Stocks news story on Melinta Therapeutics »

Stonepine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

MLNT

Melinta Therapeutics

$2.62

-0.055 (-2.06%)

07:28
11/01/18
11/01
07:28
11/01/18
07:28
Recommendations
Melinta Therapeutics analyst commentary at H.C. Wainwright »

Melinta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

MLNT

Melinta Therapeutics

$2.79

-0.28 (-9.12%)

08:12
10/29/18
10/29
08:12
10/29/18
08:12
Hot Stocks
Melinta Therapeutics announces results from Phase 3 Baxdela trial »

Melinta Therapeutic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.